SCHEMBL5486177

SCHEMBL5486177

CCC(=O)Oc1cc(OC)c(OC)cc1C(=O)c1ccc(I)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 1/20 0.41
ELANE P08246 1/20 0.41
POLB P06746 1/20 0.41
FGFR1 P11362 1/20 0.41
VCP P55072 1/20 0.41
TSHR P16473 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HMGCR P04035 1/20 0.40
GAA P10253 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ACHE P22303 1/20 0.39
ALOX15 P16050 1/20 0.39
RECQL P46063 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5484960 0.86 KMT2A (0.49) MAPTHTTNPSR1ALDH1A1NPC1
SCHEMBL5486182 0.86 ELANE (0.54) MAPTHTTNPSR1ALDH1A1ELANE
SCHEMBL6617275 0.86 TSHR (0.53) MAPTHTTNPSR1ALDH1A1NPC1
SCHEMBL19028019 0.78 FGFR1 (0.53) MAPTFGFR1VCPTSHRCYP3A4
SCHEMBL5484029 0.78 MAPT (0.50) MAPTHTTNPSR1ALDH1A1NPC1
SCHEMBL5486173 0.76 POLB (0.46) MAPTHTTNPSR1ALDH1A1NPC1
SCHEMBL5484025 0.76 MAPT (0.47) MAPTHTTNPSR1ALDH1A1NPC1
SCHEMBL27708026 0.75 TNFSF11 (0.52) FGFR1VCPTSHRCYP3A4CYP1A2
SCHEMBL5490326 0.73 CDC25B (0.50) ALDH1A1CYP2C9GAAKMT2A
SCHEMBL7410935 0.71 POLB (0.62) MAPTHTTNPSR1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250410-B2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof VIA PHARMACEUTICALS, INC. (US) 2007-07-31 US disclosed
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof PDE7A, PDE3B, PDE3A MAPT 4388/4885HTT 4305/4885NPSR1 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.